TSIEX02:	Study Treatment Administration; Safety Analysis Set (Study jjcs - core)					
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
Parameter 	N=53 	N=73 	N=126 	N=59 	
Total dosing days of treatment (excluding days off treatment)a 	 	 	 	 	
N 	53 	73 	126 	59 	
Mean (SD) 	99.0 (57.97) 	106.7 (56.44) 	103.4 (56.98) 	93.8 (59.12) 	
Median 	97.0 	103.0 	102.5 	76.0 	
Min, max 	1, 197 	6, 198 	1, 198 	7, 200 	
Interquartile range 	48.0, 142.0 	60.0, 159.0 	55.0, 154.0 	51.0, 151.0 	
 	 	 	 	 	
Cumulative dose ([unit]) 	 	 	 	 	
N 	53 	73 	126 	59 	
Mean (SD) 	2799.3 (1430.11) 	2558.4 (1472.53) 	2659.7 (1453.97) 	2520.5 (1474.47) 	
Median 	3301.0 	2465.0 	2884.5 	2660.0 	
Min, max 	298, 4927 	102, 4978 	102, 4978 	187, 4963 	
Interquartile range 	1561.0, 3984.0 	1177.0, 3859.0 	1326.0, 3914.0 	1118.0, 4098.0 	
 	 	 	 	 	
Average daily dose ([unit/day]) (including days off treatment) 	 	 	 	 	
N 	53 	73 	126 	59 	
Mean (SD) 	24.57 (11.958) 	24.36 (9.463) 	24.45 (10.539) 	27.44 (10.456) 	
Median 	23.20 	23.60 	23.40 	28.20 	
Min, max 	5.2, 44.9 	5.1, 44.2 	5.1, 44.9 	6.7, 44.5 	
Interquartile range 	13.80, 35.90 	17.40, 30.20 	16.20, 32.70 	19.50, 35.90 	
 	 	 	 	 	
Average daily dose ([unit/day]) (excluding days off treatment) 	 	 	 	 	
N 	53 	73 	126 	59 	
Mean (SD) 	27.43 (12.232) 	30.60 (12.574) 	29.27 (12.482) 	23.88 (12.279) 	
Median 	25.70 	30.30 	28.10 	21.90 	
Min, max 	6.2, 49.6 	5.0, 50.0 	5.0, 50.0 	6.3, 49.9 	
Interquartile range 	18.20, 39.00 	20.40, 41.80 	19.30, 39.40 	12.80, 34.10 	
 	 	 	 	 	
Modal daily dose ([unit/day]), n (%) 	 	 	 	 	
N 	53 	73 	126 	59 	
20 mg 	18 (34.0%) 	19 (26.0%) 	37 (29.4%) 	17 (28.8%) 	
30 mg 	11 (20.8%) 	15 (20.5%) 	26 (20.6%) 	14 (23.7%) 	
40 mg 	24 (45.3%) 	39 (53.4%) 	63 (50.0%) 	28 (47.5%) 	
 	 	 	 	 	
Final daily dose ([unit/day]) 	 	 	 	 	
N 	53 	73 	126 	59 	
Mean (SD) 	32.6 (10.50) 	29.1 (10.55) 	30.6 (10.63) 	28.5 (12.33) 	
Median 	34.0 	27.0 	31.0 	27.0 	
Min, max 	11, 49 	12, 49 	11, 49 	10, 49 	
Interquartile range 	25.0, 40.0 	21.0, 37.0 	22.0, 38.0 	17.0, 40.0 	
 	 	 	 	 	
Final daily dose ([unit/day]), n (%) 	 	 	 	 	
20 mg 	8 (15.1%) 	18 (24.7%) 	26 (20.6%) 	20 (33.9%) 	
30 mg 	14 (26.4%) 	22 (30.1%) 	36 (28.6%) 	13 (22.0%) 	
40 mg 	31 (58.5%) 	33 (45.2%) 	64 (50.8%) 	26 (44.1%) 	

a Total dosing days of treatment is defined as the total number of days study treatment received – number of days off study treatment. 	
a Total dosing days of treatment is defined as the total number of days study treatment received – number of days off study treatment.	
a Total dosing days of treatment is defined as the total number of days study treatment received – number of days off study treatment.	
a Total dosing days of treatment is defined as the total number of days study treatment received – number of days off study treatment.	
a Total dosing days of treatment is defined as the total number of days study treatment received – number of days off study treatment.